Suppr超能文献

T-705 核糖三磷酸针对流感病毒 RNA 聚合酶的作用机制。

Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.

机构信息

Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan.

出版信息

Antimicrob Agents Chemother. 2013 Nov;57(11):5202-8. doi: 10.1128/AAC.00649-13. Epub 2013 Aug 5.

Abstract

T-705 (favipiravir; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) selectively and strongly inhibits replication of the influenza virus in vitro and in vivo. T-705 has been shown to be converted to T-705-4-ribofuranosyl-5-triphosphate (T-705RTP) by intracellular enzymes and then functions as a nucleotide analog to selectively inhibit RNA-dependent RNA polymerase (RdRp) of the influenza virus. To elucidate these inhibitory mechanisms, we analyzed the enzyme kinetics of inhibition using Lineweaver-Burk plots of four natural nucleoside triphosphates and conducted polyacrylamide gel electrophoresis of the primer extension products initiated from (32)P-radiolabeled 5'Cap1 RNA. Enzyme kinetic analysis demonstrated that T-705RTP inhibited the incorporation of ATP and GTP in a competitive manner, which suggests that T-705RTP is recognized as a purine nucleotide by influenza virus RdRp and inhibited the incorporation of UTP and CTP in noncompetitive and mixed-type manners, respectively. Primer extension analysis demonstrated that a single molecule of T-705RTP was incorporated into the nascent RNA strand of the influenza virus and inhibited the subsequent incorporation of nucleotides. These results suggest that a single molecule of T-705RTP is incorporated into the nascent RNA strand as a purine nucleotide analog and inhibits strand extension, even though the natural ribose of T-705RTP has a 3'-OH group, which is essential for forming a covalent bond with the phosphate group.

摘要

T-705(法匹拉韦;6-氟-3-羟基-2-吡嗪甲酰胺)在体外和体内选择性且强烈抑制流感病毒的复制。已证明 T-705 被细胞内酶转化为 T-705-4-核糖呋喃基-5-三磷酸(T-705RTP),然后作为核苷酸类似物选择性抑制流感病毒的 RNA 依赖性 RNA 聚合酶(RdRp)。为了阐明这些抑制机制,我们使用四种天然核苷三磷酸的 Lineweaver-Burk 图分析了抑制的酶动力学,并进行了从(32)P 放射性标记的 5'Cap1 RNA 起始的引物延伸产物的聚丙烯酰胺凝胶电泳。酶动力学分析表明,T-705RTP 以竞争性方式抑制 ATP 和 GTP 的掺入,这表明 T-705RTP 被流感病毒 RdRp 识别为嘌呤核苷酸,并以非竞争性和混合方式分别抑制 UTP 和 CTP 的掺入。引物延伸分析表明,单个 T-705RTP 分子掺入流感病毒新生 RNA 链中,并抑制随后核苷酸的掺入。这些结果表明,单个 T-705RTP 分子作为嘌呤核苷酸类似物掺入新生 RNA 链中,并抑制链延伸,尽管 T-705RTP 的天然核糖具有 3'-OH 基团,该基团对于与磷酸基团形成共价键是必需的。

相似文献

2
The mechanism of resistance to favipiravir in influenza.流感病毒对法匹拉韦耐药的机制。
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11613-11618. doi: 10.1073/pnas.1811345115. Epub 2018 Oct 23.
6
Mechanism of action of T-705 against influenza virus.T-705抗流感病毒的作用机制。
Antimicrob Agents Chemother. 2005 Mar;49(3):981-6. doi: 10.1128/AAC.49.3.981-986.2005.

引用本文的文献

1
Green synthesis of structural analogs of favipiravir.法匹拉韦结构类似物的绿色合成。
RSC Adv. 2025 May 27;15(22):17570-17579. doi: 10.1039/d5ra02613j. eCollection 2025 May 21.
2
PA and PA-X: two key proteins from segment 3 of the influenza viruses.PA和PA-X:流感病毒第3节段的两种关键蛋白。
Front Cell Infect Microbiol. 2025 Mar 14;15:1560250. doi: 10.3389/fcimb.2025.1560250. eCollection 2025.
5
SARS-CoV-2 Resistance to Small Molecule Inhibitors.严重急性呼吸综合征冠状病毒2对小分子抑制剂的耐药性。
Curr Clin Microbiol Rep. 2024 Sep;11(3):127-139. doi: 10.1007/s40588-024-00229-6. Epub 2024 Jun 24.

本文引用的文献

3
T-705 (favipiravir) inhibition of arenavirus replication in cell culture.T-705(法匹拉韦)抑制细胞培养中的沙粒病毒复制。
Antimicrob Agents Chemother. 2011 Feb;55(2):782-7. doi: 10.1128/AAC.01219-10. Epub 2010 Nov 29.
4
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.T-705(法匹拉韦)对致死性 H5N1 流感 A 病毒的活性。
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):882-7. doi: 10.1073/pnas.0909603107. Epub 2009 Dec 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验